Anil A. Joy

A randomized trial comparing four-weekly versus 12-weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration-resistant prostate cancer.

B. Hutton, C. Canil, D. Fergusson, 2019, Journal of Clinical Oncology.

Cancer therapy disparity: unequal access to breast cancer therapeutics and drug funding in Canada

S. Verma, A. Joy, S. Sehdev, 2007, Current oncology.

Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines.

S. Verma, S. Chia, A. Joy, 2018, Current oncology.

Models of care for early-stage breast cancer in Canada.

S. Verma, L. Sidéris, A. Joy, 2011, Current oncology.

Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study

G. Pond, S. Damaraju, B. Hutton, 2018, Supportive Care in Cancer.